



The Medical Applications of Novel PET Radiopharmaceuticals

Guest Editors:

Dr. Jonathan Vigne

1. Department of Nuclear
Medicine, CHU de Caen
Normandie, Normandie
Université, UNICAEN, 14000 Caen,
France

2. PhIND, Centre Cyceron, Institut
Blood and Brain @ Caen-
Normandie, INSERM U1237,
14000 Caen, France

Dr. Florent L. Besson

School of Medicine, Université
Paris-Saclay, 94270 Le Kremlin-
Bicêtre, France

Deadline for manuscript
submissions:

25 August 2024

Message from the Guest Editors

Dear Colleagues,

This medical field is constantly seeking innovative solutions to improve diagnostic and treatment using tailored approaches. One such advancement lies in the utilization of novel positron emission tomography (PET) radiotracers. These cutting-edge radiotracers have shown immense potential in revolutionizing medical applications. With the rapid development of medical imaging technologies, PET has emerged as a powerful tool for visualizing and quantifying physiological processes within the human body. Traditional PET radiotracers have been widely used to diagnose and monitor various conditions. These innovative radiotracers are designed to target specific molecular and cellular processes, allowing for more accurate and precise imaging. This Special Issue aims to explore the significance and impact of novel PET radiotracers toward various medical applications. It is open to original research and review articles. We look forward to receiving your contributions.

Dr. Jonathan Vigne

Dr. Florent L. Besson

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com